Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase NA 6Phase 4 6Phase 3 4Phase 1 3

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Endocrine 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Carcinoid Tumor 1Adenoma, Islet Cell 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × OTHER × Octreotide × Clear all
NCT03879694 2026-02-06

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Roswell Park Cancer Institute

Phase 1 Completed
19 enrolled

Adenoma, Islet Cell

NCT03057509 2019-06-21

A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors

Massachusetts General Hospital

Phase 1 Withdrawn
Endocrine

Carcinoid Tumor

NCT00008073 2013-12-19

Octreotide and Doxorubicin in Treating Patients With Advanced Cancer

University of Pittsburgh

Phase 1 Completed
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡